Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$8.29 ▼ -0.45
(-5.15%)
MKT CAP: $9.26B • VOL: 8.96M
52W L $2 52W H $12
IBRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $113.3M | $14.7M | $622.0K |
| YoY Revenue Growth % | +668.3% | +2270.6% | — |
| Gross Profit | $112.5M | $14.7M | — |
| Gross Margin % | 99.3% | 100.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$256.0M | -$344.2M | -$362.3M |
| Operating Margin % | -226.0% | -2334.2% | -58239.5% |
| Net Income (GAAP) | -$351.5M | -$413.6M | -$583.9M |
| EBITDA (Normalized) | -$253.0M | -$338.7M | -$362.2M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$304.9M | -$391.2M | -$366.8M |
| Capital Expenditures (CapEx) | $3.8M | $6.9M | $28.0K |
| Free Cash Flow (FCF) | -$308.8M | -$398.1M | -$366.8M |
| FCF Margin % | -272.6% | -2700.1% | -58968.6% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -9.3% |
| Cash & Short-Term Equivalents | $88.3M | $143.4M | — |
| Total Debt (Short + Long Term) | $450.7M | $392.0M | $1.19B |
| Total Stockholders' Equity | -$500.5M | -$489.1M | $2.45B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IBRX.